Related Experiment Video

Updated: Jan 20, 2026

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.2K

Decreased DHRS2 expression is associated with HDACi resistance and poor prognosis in ovarian cancer

Yingyan Han1, Zhi Wang1, Shujuan Sun1

  • 1Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Epigenetics
|August 20, 2019
PubMed

Insights

High expression of histone deacetylases (HDACs) correlates with poor ovarian cancer (OC) outcomes. HDAC inhibitors show promise, particularly in patients with high DHRS2 expression, indicating potential for personalized OC treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Histone deacetylases (HDACs) are implicated in various cancers.
  • HDAC inhibitors (HDACi) exhibit anti-cancer properties but their role in ovarian cancer (OC) is not well-defined.
  • Personalized treatment strategies for OC require further investigation.

Purpose of the Study:

  • To investigate the correlation between HDAC expression and OC patient outcomes.
  • To explore the potential of HDAC inhibitors in OC treatment.
  • To identify biomarkers predicting response to HDAC inhibitors in OC.

Main Methods:

  • Correlation analysis of HDAC expression with OC patient outcomes.
  • Assessment of DHRS2 mRNA and protein levels following HDAC inhibitor treatment.
  • In vitro studies evaluating the impact of DHRS2 suppression on OC cell sensitivity to HDAC inhibitors.

Main Results:

  • High HDAC expression is linked to poor OC outcomes, suggesting HDAC inhibitors as a therapeutic avenue.
  • HDAC inhibitors increase DHRS2 expression (mRNA and protein) in OC cells.
  • DHRS2 suppression reduces OC cell sensitivity to HDAC inhibitors by affecting Mcl-1 inhibition.
  • Decreased DHRS2 expression in OC tissues correlates with poorer outcomes and chemotherapy response.

Conclusions:

  • HDAC inhibitors show therapeutic promise for ovarian cancer.
  • DHRS2 is a key mediator of HDAC inhibitor sensitivity in OC.
  • High DHRS2 expression may predict favorable response to HDAC inhibitors in OC patients, offering a potential biomarker for personalized therapy.
Keywords:
DHRS2HDACiOvarian cancerPrognosis

More Related Videos

An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses10:35

An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses

Published on: November 28, 2010

18.8K
In vitro Enrichment of Ovarian Cancer Tumor-initiating Cells11:37

In vitro Enrichment of Ovarian Cancer Tumor-initiating Cells

Published on: February 18, 2015

14.2K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Decreased Body Temperature01:29

Decreased Body Temperature

A decreased body temperature can occur in patients with hypothermia and frostbite. Heat loss with extended cold exposure overpowers the body's ability to create heat, resulting in hypothermia. Core temperature readings help classify hypothermia. Mild hypothermia is temperatures between 32 °C (89.6 °F) and 35°C (95 °F) and is caused by impaired thermoregulation. Moderate hypothermia is temperatures between 28 C (82.4 °F) and 32 °C (89.6 °F) caused by...
1.0K
Decreased pulse rate01:14

Decreased pulse rate

Bradycardia is a medical condition in which the heart rate is slower than normal. It occurs when the heart's natural pacemaker, the sinus node, generates slower electrical impulses than the standard rhythm. In adults, bradycardia is diagnosed when the pulse rate falls below 60 beats per minute, indicating a deviation from the normal heart rate range.
There are specific risk factors that can elevate the likelihood of developing bradycardia. Advanced age is a significant factor, with...
852
Resistivity01:22

Resistivity

When a voltage is applied to a conductor, an electrical field is generated, and charges in the conductor feel the force due to the electrical field. The current density that results depends on the electrical field and the properties of the material. In some materials, including metals at a given temperature, the current density is approximately proportional to the electrical field. In these cases, the current density can be modeled as:
4.4K
Resistance01:19

Resistance

When a current moves through any conductor, the conductor causes some level of difficulty for the current to flow. The measure of that difficulty is known as the resistance of the material and is represented by R. Every material has its own resistance. In the case of conductors, heat is emitted whenever a current passes through them. Resistance depends on the resistivity of the material. Resistivity is a characteristic of the material used to fabricate electrical components, whereas the...
5.7K
Ovarian Cycle01:27

Ovarian Cycle

The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle...
3.5K